Investigational drug · Phase 3
TS-172
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hyperphosphatemia Patients on Hemodialysis.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
14
Any phase or sponsor naming "TS-172"
First trial start
2025
Jan 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TS-172", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hyperphosphatemia Patients on Hemodialysis
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "TS-172" as an intervention, largest first.
- A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on HemodialysisPivotal-lookingCompleted
Taisho Pharmaceutical Co., Ltd.Industry
NCT05699239 · 326 participants · Start Feb 8, 2023 · Primary completion Dec 26, 2023
Drug: TS-172 10mg bid; TS-172 30mg bid and 3 more · For: Hyperphosphatemia Patients on Hemodialysis
Sites: Tokyo, Japan
- A Long-term Study of TS-172 in Hyperphosphatemia Patients on HemodialysisPivotal-lookingRecruiting
Taisho Pharmaceutical Co., Ltd.Industry
NCT07285304 · 300 participants (planned) · Start Dec 1, 2025 · Primary completion Jul 31, 2027
Drug: TS-172 · For: Hyperphosphatemia Patients on Hemodialysis
Sites: Tokyo, Japan
- A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on HemodialysisPivotal-lookingCompleted
Taisho Pharmaceutical Co., Ltd.Industry
NCT06745531 · 101 participants · Start Jan 6, 2025 · Primary completion Oct 13, 2025
Drug: TS-172 20~60 mg/day; Placebo · For: Hyperphosphatemia Patients on Hemodialysis
Sites: Tokyo, Japan
- A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate BindersPivotal-lookingRecruiting
Taisho Pharmaceutical Co., Ltd.Industry
NCT07285291 · 100 participants (planned) · Start Jan 9, 2026 · Primary completion Dec 22, 2026
Drug: TS-172 20~60 mg/day; Placebo · For: Hyperphosphatemia Patients on Hemodialysis
Sites: Tokyo, Japan
- A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate BindersCompleted
Taisho Pharmaceutical Co., Ltd.Industry
NCT06745518 · 62 participants · Start Jan 6, 2025 · Primary completion Jul 15, 2025
Drug: TS-172; Placebo · For: Hyperphosphatemia Patients on Hemodialysis
Sites: Tokyo, Japan
Taisho Pharmaceutical Co., Ltd.Industry
NCT06837155 · 52 participants · Start Mar 3, 2025 · Primary completion May 20, 2025
Drug: TS-172 20 mg; TS-172 90 mg and 2 more · For: Healthy Volunteers
Sites: Tokyo, Japan
Taisho Pharmaceutical Co., Ltd.Industry
NCT04979572 · 41 participants · Start Aug 16, 2021 · Primary completion Jan 26, 2022
Drug: TS-172; Placebo · For: Healthy Adult Subjects
Sites: Toshima-ku, Japan
- A Clinical Study of TS-172 in Hyperphosphatemia Patients on HemodialysisPivotal-lookingActive, not recruiting
Taisho Pharmaceutical Co., Ltd.Industry
NCT07548840 · 34 participants · Start May 8, 2026 · Primary completion Nov 30, 2026
Drug: TS-172 20~60 mg/day · For: Hyperphosphatemia Patients on Hemodialysis
Sites: Tokyo, Japan
- A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal DialysisPivotal-lookingRecruiting
Taisho Pharmaceutical Co., Ltd.Industry
NCT07548853 · 30 participants (planned) · Start May 13, 2026 · Primary completion May 31, 2027
Drug: 'TS-172 20~60 mg/day · For: Hyperphosphatemia Patients on Peritoneal Dialysis
Sites: Tokyo, Japan
Taisho Pharmaceutical Co., Ltd.Industry
NCT06837142 · 30 participants · Start Mar 11, 2025 · Primary completion Apr 30, 2025
Drug: Triazolam and TS-172; TS-172 and itraconazole · For: Healthy Male Subjects
Sites: Tokyo, Japan
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hyperphosphatemia Patients on Hemodialysis
- TS-172 20~Phase 34 trials
Taisho Pharmaceutical Co., Ltd. · Hyperphosphatemia Patients on Hemodialysis, Hyperphosphatemia Patients on Peritoneal Dialysis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.